A Phase 1b/2a Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Nivolumab (Primary) ; X4P 001 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors X4 Pharmaceuticals
- 24 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
- 24 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.